




WHO STUDY GROUP ON RHEUMATIC FEVER/
RHEUMATIC HEART DISEASE

Geneva: 30 March - 4 April 1987



THE PROBLEM OF RF/RHD IN THE EASTERN MEDITERRANEAN REGION
By H.A. Majeed FRCPI, DCH, Paediatric Department,
Faculty Of Medicine, University Of Kuwait,
P.O. Box 24923, 13110 Safat, Kuwait.

EPIDEMIOLOGY

(1) SOCIO-ECONOMIC FACTORS

It is now generally accepted that acute rheumatic fever (RF) is essentially a social disease. This concept is not new. In 1920, Poynton commented "the rarity of these cases of acute rheumatism in children in private practice as compared with hospital practice would form an interesting subject for inquiry" (1). In 1930 Glover wrote: "no disease has clearer cut social incidence than acute rheumatism. The incidence of acute rheumatism increases directly with poverty, malnutrition, overcrowding and bad housing" (2). The studies of Gordis et al (1969) in Baltimore (USA) showed that "race did not play a role in the epidemiology of RF, and that crowding or some factor related to it was one of the main environments of rheumatic fever incidence" (3,4). Until only few decades ago, RF was described as a disease of the temperate climates, and was thought to be rare in the tropics and subtropics (5-7). The high incidence and prevalence of RF and rheumatic heart disease (RHD), subsequently reported from the tropics and subtropics (mostly developing) showed that this concept was erroneous (8-23). Instead, it has been realised that overcrowding and poverty are the two most important factors in the epidemiology of RF/RHD through out the world (24-26). However, in the world of RF/RHD, the old terminology of "temperate" and "tropical and subtropical", has been changed to "developed" and "developing". The new terminology is as misleading as the old. According to Disciascio and Taranta, "developing is a wishful thinking kind of word, as many developing countries are developing imperceptibly. We prefer the term "poor" which is what is usually meant" (26). Even in the most affluent countries, where pockets of poverty still exist, the eradication of RF/RHD remained an "unfulfilled hope" (27). Because of this strong impact of "poverty" on the epidemiology of RF, the battle against the disease is not likely to be won by the Medical profession, even world wide, alone. Politicians, especially in the "developing" or "poor" countries should probably be involved.

(2) THE STREPTOCOCCAL PROBLEM

2.1 The Streptococcal Infections :

The epidemiology of RF, closely follows that of group A streptococcal (GAS) upper respiratory tract infections. The incidence of RF is greatly influenced by the proportional incidence of GAS pharyngitis mainly in the childhood population and the magnitude of the host antistreptococcal immune response. The proportional incidence of GAS pharyngitis and the magnitude of the antistreptococcal immune responses in the countries of the Eastern Mediterranean Region are essentially similar to that of other countries (table 1 and 2). In spite of this, the incidence of RF in the Eastern Mediterranean Region is higher than elsewhere (Table 3). This most probably reflects a high frequency of upper respiratory tract infections amongst the childhood population of such communities caused by a wide spread of infection, under the situations of poverty, particularly poor housing and overcrowding. This will be associated with a relatively higher incidence of GAS pharyngitis.

The issue of this document does not constitute formal publication. It should not be reviewed, abstracted, quoted or translated without the agreement of the World Health Organization. Authors alone are responsible for views expressed in signed articles.

Ce document ne constitue pas une publication. Il ne doit faire l'objet d'aucun compte rendu ou résumé ni d'aucune citation ou traduction sans l'autorisation de l'Organisation mondiale de la Santé. Les opinions exprimées dans les articles signés n'engagent que leurs auteurs.

2.2 The Streptococcal Carrier Ship

The hemolytic streptococcal (all groups) carriership in tropical and subtropical (mostly poor) areas seems to be higher than that in temperate climate (mostly affluent) (39). Furthermore the prevalence of groups C and G is higher in the tropics and subtropics (39). Table 4. Shows that the pattern of prevalence in temperate climates is different from that in the tropics and subtropics. The prevalence of group A ranged between 54-61% in temperate climates against 14-30% in the temperate climates against 65 - 77% in the tropics and subtropics. What does this mean? The answer is far from clear. However it seems that further work on the pathogenicity of groups C and G, together with close follow-up of these patients, is needed in countries where the prevalence of these two is high.

2.3 The Rheumatogenic Strains

The concept of a nephritogenic potential (nephritogenicity) of some streptococcal strains, based on significantly higher attack rates of acute glomerulonephritis (AGN) following GAS pharyngitis was pioneered by Rammelkamp and associates in 1952 (46, 47). This was soon supported by the findings that AGN following GAS pharyngitis was predominantly caused by a limited number of streptococcal strains mainly M12, M1 and M4. These types were called pharyngeal nephritogenic strains (48). Similarly, and soon after the term "impetigo strains" was coined by Parker and associates, based on the findings that a limited number of M non typable serotypes mainly belonging to the complex patterns T3/13/B3264, T/8/25/Imp. 19 and T5/27/44, accounted for the majority of cases of impetigo (49). This was supported by Dillon et al who, in addition, showed that these impetigo strains were different from those isolated from the throat of children with respiratory infections, in the same population (50). Subsequently many M typeable impetigo strains (e.g. M types 49,52,53,54,57 etc) were identified as nephritogenic (51-56). If there are nephritogenic and non-nephritogenic strains, another question must be raised: are there, similarly, rheumatogenic and non-rheumatogenic strains? The question is justified at least by observation that though both acute rheumatic fever (RF) and AGN follow group A beta haemolytic streptococcal (BHS) infection, rarely occur together simultaneously in the same patient at the same time (56, 57). However the concept of "rheumatogenicity" is less clear (57), though it gained a supporting epidemiological evidence from studies by Bisno et al and Majeed et al (58, 59). Do some group A streptococci vary in their "rheumatogenicity" as they do in "nephritogenicity"? In a recent review of the literature Bisno showed, that the number of streptococcal M types associated with well documented outbreaks of pharyngitis leading to AF was surprisingly small e.g. M types 5, 18, 19 and 24 (60). Furthermore, review of such outbreaks revealed that these serotypes (M types, 5,18,19 and 24) were frequently and consistently associated with RF, whereas other which are equally prevalent in the population (e.g. M12) have been rarely if ever implicated (60). Moreover in the pre-antibiotic era there are a number of epidemics of streptococcal pharyngitis in which infection not only failed to elicit first attacks of RF, but also failed to precipitate a recurrence in rheumatic patients (60). However the recent experience in Kuwait (59) showed that the majority of the group A streptococcal isolates from patients with RF, were M,T and SOf non-typable. The need for studying and identifying such non-typable strains is obvious.

THE INCIDENCE

The diagnosis of RF remains mainly clinical, as no specific diagnostic test, as yet, is available. Although the Revised Jones's Criteria (61) have certainly been helpful, over diagnosis and under diagnosis, are still unavoidable. Furthermore, the absence of efficient medical care delivery systems, serving the population at risk i.e. the "poor", makes it more difficult to obtain reliable data on the incidence and prevalence of RF and RHD in the Eastern Mediterranean Area. Taking this into consideration, the data on the incidence and prevalence of RF and RHD, from the Eastern Mediterranean Area (Table 3) should be viewed with caution. However, reliable data can be obtained in countries, where the medical care delivery system has been improving. Perhaps the recent experience in Kuwait, may serve as an example. Starting 1984, reliable data on the incidence of RF in Kuwait could be obtained. This was achieved by the establishment of a National Committee for the prevention of RF. Among the Committee members were the chairmen of all Paediatric departments of the regional hospitals

in Kuwait, the physicians in charge of the primary care centres and the child welfare centres (0-12 years) an epidemiologist and a statistician. The policy of the Committee, stressed that the prevention of RF should be an integral part of the primary care delivery system. This insured that all children suspected of developing RF in the primary care and child welfare centres, were referred to the paediatric departments of the regional hospitals, where the diagnosis was assessed. The revised Jones's Criteria (61) were accepted as the diagnostic criteria to be used by all. Statistics, prepared by the chairmen of the paediatric departments were collected and assessed once every three months. This insured, reasonably reliable data, and at the same time decreased the chances of missing cases in the primary care centres. Through this, it was possible to estimate the annual incidence of RF in the country as 39/100.000 and 31/100.000 childhood population (5 - 14 years) in the years 1984 and 1985 respectively (62).

THE CLINICAL PICTURE

Recently studies from "developed" countries have reported a decreasing incidence and severity of RF (63-67). In contrast, reports from the Eastern Mediterranean Region described a different clinical profile in which the incidence and severity of carditis, congestive heart failure and mortality were high. However the studies from the Eastern Mediterranean Region were retrospective, reported from tertiary referral centres, and have failed to differentiate between initial attacks, recurrences, and already established cases of RHD (8-16). Recent prospective studies of the INITIAL attack of RF, from the same region (18,19), reported a mild form of the disease, similar to that described in developed countries (Table 5), and attributed this to the prospective design of their studies and the inclusion of initial attack only in a general pediatric population (18,19). The low mortality rate (0.5% and 0.9%) reported in the two recent prospective studies (18,19), contrasted sharply with the high mortality rate reported from neighbouring countries (Table 5). Similarly, studies from the Eastern Mediterranean Region reported a high prevalence of RHD with the development of EARLY cardiac surgery in children and adolescents (12-14). These findings were different from those from developed countries, giving rise to the possibility that the evolution of RHD behaved differently in this Region with a tendency for earlier development of a severe valvular RHD (12-14). These studies, however, were retrospective in nature, reported from tertiary referral centres and no effort was made to differentiate between initial attack and recurrences. These findings have been challenged by two recent studies (70,71). Data from these studies (70,71) showed that the evolution of RHD in the Eastern Mediterranean Region (tropics and subtropics) was not different from that described earlier in the developed countries or countries with temperate climate (Table 6). Analysis of the recent studies (70,71) from the Region and comparison to those reported from other countries, clearly showed that when the initial attack of RF was studied in the general childhood population (to avoid bias seen in tertiary referral centres) while carefully excluding recurrences and already established case of RHD, and with patients followed up the same group of physicians (to avoid subjective auscultatory differences) in a prospective way, and insuring compliance with secondary prophylaxis, the evolution of RHD following the initial attack of RF behaved similarly in the different climates and countries (Table 6). The higher prevalence of RHD and the early development of severe valvular involvement, seen in the "developing" countries, probably reflect the well documented role of recurrence in inflicting further cardiac valvular damage (75-77) and illustrates the failure of the medical care delivery system in protecting the rheumatic children from recurrences.

PREVENTION

There are four known strategies for prevention of RF/RHD :

1. Primary Prophylaxis
2. Secondary Prophylaxis
3. Vaccination
4. Improvement of the socioeconomic status of the population at risk.

PRIMARY PROPHYLAXIS

Pharyngitis is a common disease in the community, especially in childhood. The annual incidence of pharyngitis in all school-aged children is estimated to be around 11%(78). Twenty percent of pharyngitis in such children is caused by GAS and 80% by non-bacterial, presumably viral agents (28-31). The role of GAS in the aetio-pathogenesis of RF is beyond dispute (79). The concept of primary prophylaxis is based on the findings of the well documented studies of Denny (80) and Wannamaker (81). Data from these studies have shown that when antibiotics were given early in the course of GAS pharyngitis, a significant drop in the attack rate of RF was achieved (80, 81). Thus primary prophylaxis is an ideal form of prevention. However, several problems have rendered it a difficult goal to achieve. The main problem comes from the unreliability of differentiating GAS pharyngitis from viral pharyngitis on clinical ground alone (29, 82-84). A recent study of current primary prophylaxis, based on clinical judgement alone, in a primary care clinic in Kuwait, has revealed disturbing data (29). Data from this study showed a very high false positive diagnosis of GAS pharyngitis (76%). This implied that the great majority of patients with pharyngitis would have been given unnecessary antibiotics. On the other hand, a similar high false negative (46%) diagnosis of GAS pharyngitis, implied that almost half of the patients with GAS pharyngitis would have been denied antibiotic treatment with the possibility that some would develop the sequelae. The introduction of bacteriological diagnostic facilities in primary care clinics is a tempting solution to the problem. However this also has two difficulties. The first is that it is costly and may not prove to be cost-effective. The second is that, standard bacteriological diagnostic facilities, for the diagnosis of GAS pharyngitis, necessitate a period of 48 hours, before the results are available. This necessitates a second visit to the clinic. In the experience of many, including ourselves, parents were reluctant to make a second visit. This leaves the current primary prophylaxis regimen with many difficulties. There is a room for hope however, a newly introduced direct swab test for the detection of GAS directly from the throat has proved to be highly sensitive and specific and could be carried out in two minutes (85). This is expected to solve the important diagnostic problem. Furthermore a recent study from Kuwait has shown that a single intramuscular injection of benzathine penicillin in the treatment of GAS pharyngitis was successful in 97% of cases (29). This is expected to solve the therapeutic problem of non-compliance to a 10 days course of oral penicillin. Based on the results of these two studies (29, 85), a new regimen based on the rapid diagnosis of GAS pharyngitis, by the two minute direct swab test and the prompt effective treatment of GAS pharyngitis by a single intra-muscular injection of benzathine penicillin may make primary prophylaxis a practical possibility. However, in the light of the experience of other investigators, where only a minority of patients with pharyngitis sought medical advice a complete success of "Primary Prophylaxis" with total eradication of RF in the community should not be expected (86).

SECONDARY PROPHYLAXIS

This aims at prevention of recurrences. The recurrences of RF are now, well known to be precipitated by new streptococcal infections (79). However not all strains of GAS are capable of precipitating a recurrence(60). In the natural history of RF and before the antibiotics era, the recurrence rate varied between 66-85%(87-89). The continuous administration of antibiotics was shown to be effective in reducing the frequency of recurrences (90-93). In a recent study in which 126 children with the initial attack of ARF, were followed up prospectively for a mean period of 6 years the recurrence rate was 0.005/patient/year follow up in those patients, who maintained regular secondary prophylaxis i.e. 0.5% patient/year. Compared to 0.2/patient/year in those patients who did not maintain regular secondary prophylaxis i.e. 20% patient/year (71). Recurrences were shown not only to inflict further damage to valves already affected, but also to affect valves that escaped damage initially (71). In previous and recent studies the reduction of the prevalence rate of RHD, by secondary prophylaxis, was obvious and significant (71-74). However, to achieve such results, the questions of which antibiotic to use, the route of administration, the frequency and dose of parenteral benzathine penicillin G and the duration of secondary prophylaxis should be answered.

1. Which antibiotic ?

Sulphadiazine, in a dose of 0.5-1 gm daily, has been shown to be effective in reducing the recurrence rate to 2.8%/patient/year (94). Sulphadiazine is an inexpensive drug, but it carries with it the risk of non-compliance (oral route), emergence of resistant strains of GAS(95) and side effects. Penicillin is a superior antibiotic. It is not expensive, toxicity and hypersensitivity reactions are rare, it is effective and resistance has not been reported so far.

2. Route of administration

The oral use of penicillin V was shown to reduce the recurrence rate to 5.5%/patient/year (94). The risk of oral penicillin is non-compliance. Parenteral benzathine penicillin G has been the most commonly used in secondary prophylaxis and has been shown to be the most effective. Table 6 shows that it is still effective in the eighties as it was in the sixties.

3. How frequent should parenteral benzathine penicillin G be given ?

The once/monthly injection has been shown to be effective (Table 6). Furthermore it is easy to remember by the child and the family. However giving the injection once/3 week, has been claimed to be more effective (96). This is not easy to remember and could affect compliance. The dose of benzathine penicillin G is 1.2 million units for children aged six years or above and 600.000 units for children younger than six years.

4. How long should prophylaxis be maintained ?

To answer this question, one should consider the different variables affecting recurrences, namely the interval since the initial or antecedent attack, the presence or absence of carditis and the age of the patient. The majority of recurrences occur within the first 3-5 years after the antecedent attack. In a recent prospective study of recurrences and a mean followup period of six years, 90% occurred within the first three years, 9% in the fourth year and 1% in the fifth years (71). The concept that patients with carditis are more likely to develop recurrences than patients with no cardiac involvement has been well documented in several studies (71,97,98). However a very important question remains : does carditis develop during a recurrence, in a patient who did not manifest carditis in the initial attack? There is good evidence that if the host escapes carditis in the initial attack, he or she will continue to do so in subsequent recurrences (71, 76, 77). The age of the patient is also important. The younger the child at the time of the initial attack, the greater the likelihood of recurrence (99) and the incidence of recurrences tends to decline with age after puberty (99). Taking these factors into consideration, the regimen of secondary prophylaxis, should probably be selective: those patients with cardiac involvement in the initial attack, should continue prophylaxis at least till the age of 25 years, possibly for five years (71, 75). Because of the documented occurrence of carditis, during a recurrence, in a patient who had 'pure' chorea initially, one attack of chorea is an indication for long term prophylaxis (? till the age of 25 years) possibly for life (71,75-77). Despite the effective rate of secondary prophylaxis in reducing the incidence of occurrences and the prevalence of RHD in the community, they are still high in the Eastern Mediterranean Region (8-23). This indicates that secondary prophylaxis is not carried out faithfully on a large scale in such countries. The main cause of this is the non-availability of efficient health care systems that can reach and deliver the medical care to people at risk i.e. the poor. The cost can be projected as a problem, but it should always be stressed that prevention is much cheaper than open heart surgery and is more cost effective. It was not surprising, therefore, that the discussion taken by the RF Prevention Committee of the ISFC, during its first meeting in 1983, was to adopt secondary prophylaxis as the best and most practical means of prevention at present.

References

1. Poynton FJ : Acute rheumatism in children Br. Med J 1920, 2: 858-62.
2. Glover JA: Milroy lectures on the incidence of rheumatic diseases. The incidence of acute rheumatism. Lancet 1930, 1: 499-502.
3. Gordis L, Lilienfield A, Rodriguez R. Studies in the epidemiology and preventability of rheumatic fever. I Demographic factors and the incidence of acute rheumatic fever. J Chronic Dis 1969a, 2: 645-54.
4. Gordis L, Lilienfield A, Rodriguez R. Studies in the epidemiology and preventability of acute rheumatic fever. II Socioeconomic factors and the incidence of acute rheumatic fever. J Chronic Dis 1969b 21:655-62.
5. Paul JR, Dixon GL : Climate and rheumatic heart disease. JAMA 108: 2096, 1937.
6. Nichol ES : Geographic distribution of rheumatic fever and rheumatic heart disease in the United States. J. Lab. Clin., Med., 21 : 588, 1936.
7. Coburn AF: The factor of infection in the rheumatic state. Baltimore, 1931, Williams and Williams and Wilkins componary.
8. Abdin ZH, Essa A. Rheumatic fever and rheumatic heart disease in children below the age of five years in the tropics. Ann. Rheum Dis 1965; 24: 380-92.
9. Gharib R. Acute rheumatic fever in Shiraz. Iran. Its prevalence and characteristics in two socio-economic groups. Am. J Dis Child 1969: 118: 694-9.
10. Tehernia AC, Motamed F, Sharif H. Some clinical observations of rheumatic fever in childhood. Patterns of the disease as seen in Sourther Iran. Clin. Pediatr 1971: 10: 530-6.
11. Robinson RD, Sultana S. Abbasi AS et al. Acute rheumatic fever in Karachi. Pakistan. Am. J. Cardiol 1966; 18: 548-51.
12. Roy SB, Bhatia ML, Lazaro EJ, et al. Juvenile mitral stenosis in India. Lancet 1963; 2: 1193-5.
13. Jaishnava S, Webb JKG, Cherian J. Juvenile rheumatism in South India. A clinical study of 166 cases. Indian J. Child Health 1960; 9: 290-5.
14. Ayuthya PSN, Ratanabanangkoon K, Pongpanich B. Juvenile rheumatic fever and rheumatic heart disease at Ramathibodi Hospital. Thailand. Southeast Asian J Trop Med Pub Health 1976; 7: 77-80.
15. Guzman SV, Yason J, Viscayno JS, et al. Studies on rheumatic fever and rheumatic heart disease in the Philippines. In: Shiokawa Y & Kawakita S. eds, Proceedings of international conference on rheumatic fever and rheumatic heart disease. Japanese Circulation Society 1979: 64-8.
16. Woo KS Kong SM. Rheumatic fever (1968-1977) a ten years survey in Hong Kong. In: Shiokawa Y & Kawakita S. eds. Preceedings of the international conference on rheumatic fever and rheumatic heart disease. Japanese Circulation Society 1979: 101-4.
17. Salem B, Yousof AM, Endrys J et al. Rheumatic heart disease in Kuwait. J. Kwt Med Assoc. 1973, 7: 75-81.
18. Sanyal SK. Thapar MK, Ahmed SH, et al. The initial attack of acute rheumatic fever during childhood in North India. A prospective study of the clinical profile. Circulation 1974; 49: 7-12.
19. Majeed HA, Khan N, Dabbagh M et al. Acute rheumatic fever during childhood in Kuwait. The mild nature of the initial attacks. Ann. Trop. Paediatr, 1981, 1: 13-20.
20. Al-Bahrani IR, Thamer MA, AL-Omeri MM et al. Rheumatic heart disease in the young in Iraq Brit. Heart J 1966, 28: 824.
21. Okoroma EO, H'dede NC, Ihenacho C et al. Rheumatic fever in nigerian children. Am J Dis Child 1981, 135: 236-238.
22. ElSherif A. The epidemiological features of rheumatic fever and rheumatic heart disease in Egypt. Bull Egypt Soc Cardiol 1975, 14: 65-70.
23. Halim AM, Jacques JE. Rheumatic heart disease in the Sudan. Brit Heart J 1961, 23: 383-386.
24. Majeed HA. Acute rheumatic in Kuwait. Some clinical, epidemiological and preventive aspects. J Kwt Med Assoc 1983, 17: 3-8.
25. Majeed HA. Acute rheumatic fever the magnitude of the problem in Kuwait. In research on cardiac and renal sequelae of streptococcal infection, Majeed HA and Yousuf AM, Eds, Dustr Verlag Dr. Karl Feistle, Munchen-Deisenhofen, 1984, pp 98-115.
26. Disciascio G, Taranta A. Rheumatic fever in children. Am. Heart J., 99: 635-58, 1980.

27. Markowitz M. Eradication of rheumatic fever. An unfulfilled hope. *Circulation*, 41: 1077, 1970.
28. El-Kholy, A.M. Sorour, A.H.O. and Wannamaker, L.W.(1973): A three years prospective study of streptococcal infections in a population of rural Egyptian school children. *J. Gen. Microbiol.*, 6:101-104.
29. EL-Bahish M., Mark A, Majeed HA. Streptococcal pharyngitis in Kuwait. A pilot study in the community. *J. Kwt. Med. Assoc.* 19: 39-45, 1985.
30. Koshi, G. and Myers, R.M. (1971) : Streptococcal disease in children in South India. *Indian J. Path. Bact.*, 14:17-23.
31. Dillon, H.C. and Warren Derrick, C. (1974): Recent studies of streptococcal skin and throat infections in Alabama. In Haverkorn, M. Ed. *Streptococcal disease and the Community*. Excerpta Medica, Amsterdam, Page 266-274.
32. Behard GC, Stollerman GH. Serum inhibition of streptococcal diphosphopyridine nucleotidase in uncomplicated streptococcal pharyngitis and in rheumatic fever. *J Clin Invest* 1959; 3: 1942 - 9.
33. Limson BM, Martieres FM, and Bravo EL. Bacteriologic and immunologic comparative study of Filipino rheumatic subjects, non rheumatic subjects with group A streptococcal infections and healthy control subjects. Quoted in Stollerman GH. *Rheumatic fever and streptococcal infection*. New York: Grune and Stratton, p.84.
34. Majeed HA et al. The antistreptococcal immune responses in children with acute rheumatic fever in Kuwait. *Ann. Trop. Paediatric* 2:133-7, 1982.
35. Majeed HA, Yusuf AR, Suliman AH et al. Incidence of Acute Rheumatic Fever in Kuwait in the year 1984-1986. To be published.
36. Rotta J, Facklam RR. Manual of Microbiological diagnostic methods for streptococcal infections and their sequelae. WHO/BAC/80].
37. Schollin J, Westrom G. Acute rheumatic fever in Swedish children 1971-1980. *Acta Paediatr. Scand.* 74:749-754, 1985.
38. Mc Cormick JB, Fraser DW. Disease control programs in the United States. *JAMA* 239:2359-62, 1978.
39. Karoui, R., Majeed, H.A., Yousof, A.M., Moussa, M.A.A., Iskander, S.D. and Hussain, K. (1982): Hemolytic streptococci and streptococcal antibodies in normal school children in Kuwait. *Am. J. Epidem.*, 116:709-721.
40. Jelinkova J, Rotta J, Duben J. Long term study of the prevalence of different groups of streptococci in the general population. In: Haverkorn MJ, ed. *Streptococcal disease and the community*. Amsterdam: Excerpta Medica, 1974:198-203.
41. Valkenberg HA, Haverkorn MJ, Gosling WR, et al. Streptococcal pharyngitis in the general population. II. The attack rate of rheumatic fever and acute glomerulonephritis in patients not treated with penicillin. *J Infect Dis* 1971;124:348-57.
42. El Kholy A, Sorour AH, Houser HA, et al. A three year prospective study of streptococcal infections in a population of rural Egyptian school children. *J Clin Microbiol* 1973;6:101-10.
43. Valkenberg HA, Muller AS, Wolter CHL, et al. Streptococci in Liberia and Nigeria, West Africa. In: Haverkorn MJ, ed. *Streptococcal disease and the community*. Amsterdam: Excerpta Medica, 1974:209-14.
44. Ogunbi O, Lasi Q, Lawal SF. An epidemiological study of beta hemolytic streptococcal infections in a Nigerian (Lagos) urban population. In:Haverkorn MJ, ed. *Streptococcal disease and the community*. Amsterdam: Excerpta Media, 1974:282-4.
45. Myers RM, Koshy G. Beta-hemolytic streptococci in survey throat cultures in an Indian population. *Am J Public Health* 1961;51:1872-92.

46. Rammelkamp jr., C.H., R.S. Weaver, and J.H. Dingle: Significance of the epidemiological difference between acute nephritis and acute rheumatic fever. *Transact. Ass. Amer. Phys.* 65(1952) 168-175
47. Rammelkamp jr., C.H. and R.S. Weaver: Acute glomerulonephritis. The significance of variations in the incidence of the disease. *J. Clin. Invest.* 32(1953) 345-358
48. Wannamaker, L. W.: Epidemiology of acute glomerulonephritis. In: *Acute Glomerulonephritis, 17th Annual Symposium on the Kidney, National Foundation*, p. 39, J. Metcalf (Ed.). Little Brown, Boston (1967)
49. Parker, M. T., A.J.A. Tomlinson, and R. E. O. Williams: Impetigo contagiosa: the association of certain types of *Staphylococcus aureus* and of the *Streptococcus pyogenes* with superficial skin infections. *J. Hyg.(Camb.)* 53(1955) 458-473
50. Dillon, H.C., M.D. Moody, W.R. Maxted, and M.T. Parker: The epidemiology of impetigo and acute glomerulonephritis, *Amer. J. Epidem.* 86(1967) 710-723
51. Dillon jr., H.C.: Streptococcal infection and acute glomerulonephritis *Postgrad. Med. J.* 46(1970) 641-652
52. Hall, W.D., R.W. Bulmberg, and M.D. Moody: Studies in children with impetigo. *Amer. J. Dis. Child.* 125 (1973) 800-806
53. Lasch, E. E., V. Frankel, and V.A. Vardy: Epidemic glomerulonephritis in Israel *J. infect. Dis.* 124(1971) 141-147
54. Maxted, W. R., C.A. Fraser, and M.T. Parker: *Streptococcus pyogenes* Type 49. A nephritogenic streptococcus with a wide geographical distribution. *Lancet* i (1967) 641-644
55. Parker, M.T., D.C. Basset, W.R. Maxted, and J.D. Arne: Acute glomerulonephritis in Trinidad. Serological typing of group A streptococci. *J. Hyg.(Camb.)* 66(1968) 657-675
56. Wannamaker, L.W.: Differences between streptococcal infections of the throat and skin. *New Engl. J. Med.* 282(1970)78-85
57. Stollerman, G.H.: Nephritogenic and rheumatogenic group A streptococci *J. infect. Dis.* 120 (1969) 258-263
58. Bisno, A.L., J.A. Pearce, and H.P. Wall : Contrasting epidemiology of acute rheumatic fever and acute glomerulonephritis. Nature of the antecedent streptococcal infection. *New Engl. J. Med.* 283 (1970) 561-565
59. Majeed H.A., Khuffash F.A., Yousof A.M. : The concurrent association of group A streptococcal sero types in children with acute rheumatic fever or pharyngitis - associated glomerulonephritis and their families in Kuwait. *The Int. J. Microbiol. Hyg. (Zbl.Bakt. Hyg.A)* 1986 (in press)
60. Bisno, A.L.: The concept of rheumatogenic and nephritogenic group A Streptococci. In: *Streptococcal Diseases and the Immune Response*, pp.789-803. S. E. Read and J.B. Zabriskie (Eds.) Academic Press, New York (1980)
61. Report of the ad Hoc Committee of revised Jones Criteria (modified) of the Council of rheumatic fever and congenital heart disease of American Heart Association. *Circulation* 32 (1965) 664-668
62. Majeed H.A., Yusuf A.R., Suliman A.H. : To be published.
63. Acheson RM. The epidemiology of acute rheumatic fever 1950-1964. *J Chronic Dis* 1965, 18: 723-729.
64. Perry CB. The natural history of acute rheumatism. The Lumleian lecture of the Royal College Of Physician. *Ann Rheum Dis* 1969, 28: 471-476.
65. Sievers J, Hall P. Incidence of acute rheumatic fever. *Br. Heart J* 1971, 33:833-836.
66. Markowitz M. The changing picture of rheumatic fever. *Arth. Rheum* 20, 2 (suppliment):1977, 369-374.
67. Mayer FE, Doyle EF, Herrern L et al: Declining severity of first attack of rheumatic fever *Am J Dis Child* 1963, 105: 146-152.
68. Massel BF, Fyler DC, Roy SB. The clinical picture of rheumatic fever. Diagnosis, immediate prognosis and therapeutic implications. *Am. J. Cardiac* 1958, 1: 436-49.
69. Feinstein AR, Spagnuolo M. The clinical patterns of acute rheumatic fever, a reappraisal. *Medicine*, 1962, 41: 279-305
70. Sanyal SK, Berry AM, Duggal S, et al. Sequelae of the initial attack of acute rheumatic fever in children from North India. *Circulation* 1982, 65: 375-9.

71. Majeed HA, Yousof AM, Khuffash FA et al. The natural history of acute rheumatic fever in Kuwait: a prospective six year follow up report. *J Chron Dis* 39: 361-69, 1986.
72. UK and USA Joint Report. The evolution of rheumatic heart disease in children. Five year report of a cooperative clinical trial of ACTH, cortisone and aspirin. *Circulation* 22:503-511, 1960.
73. Feinstein AR, Wood HF, Spagnuolo M et al. Rheumatic fever in children and adolescents. A long term epidemiologic study of subsequent prophylaxis, streptococcal infection and clinical sequelae VII. Cardiac changes and sequelae. *Ann Int Med* 60:87- 1964.
74. Tompkins DG, Boxerbaum, B. Libman J. Longterm prognosis of rheumatic fever patients receiving regular intramuscular benzathine penicillin. *Circulation* 45:543- 1972.
75. Majeed, H.A., A. Shaltout, and A.M. Yousof: Recurrences of acute rheumatic fever. A prospective clinic study of 79 episodes. *Amer. J. Dis. Child.* 138 (1984) 341-345
76. Feinstein AR, Stern EK: Clinical effects of recurrent attacks of acute rheumatic fever. A prospective epidemiological study of 105 episodes. *J Chron Dis* 20: 13-27, 1967
77. Feinstein AR, Spagnuolo M: Mimetic features of rheumatic recurrences. *N Engl J Med* 262: 533-540, 1960
78. Gerber MA, Markowitz M. Management of streptococcal pharyngitis reconsidered *Pediatric infections Disease* 4:518 - 526, 1985.
79. Stollerman GH, Lewis EI, Schultz I et al. Relationship of immune response to group A streptococci to the course of acute and recurrent rheumatic fever. *Am Jmed* 20: 163 - 169, 1956.
80. Denny FW, Wannamaker LW, Brink WR et al. Prevention of rheumatic fever. Treatment of the preceding streptococcal infection, *J.A.M.A.* 143:151 - 153., 1950.
81. Wannamaker LW. Effect of eradication of the infecting type of streptococcus by specific therapy on the attack rate of acute rheumatic fever. *N. Eng J. Med.* 259:66.-71, 1958.
82. Kaplan EL, Dp FH, Dudding BA: Dignosis of streptococcal pharyngitis : differentiation of active infection from the carrier state in the symptomatic child. *J. Infect Dis* 123:490 - 494, 1971.
83. Wannamaker LW. Perplexity and precision of the diagnosis of streptococcal pharyngitis. *AM. J Dis Child* 124:352 - 358, 1972.
84. Kaplan EL. The group A upper respiratory tract carrier state : An enigma. *J Pediatr.*79:337 - 347, 1980.
85. Araj G, Majeed HA. Two-minute diagnosis of strept. A pharyngitis. *Journal of Hygiene (Camb)* In press (1986).
86. Valkenberg HA, Haverkorn MJ, Gosling WRO, et al Streptococcal pharyngitis in the general population II. The attack rate of rheumatic fever and acute glomerulo nephritis in patients not treated with penicillin. *Journal of Infections Diseases* 124: 348 - 358, 1971.
87. Roth IR, Lingg C, Whitmore A: Heart disease in children. *Am Heart J* 1937;13:36-60.
88. Bland EF, Jones TD: Rheumatic fever and rheumatic heart disease: A 20 year report on 1,000 patients followed since childhood. *Circulation* 1951;4:836-843.
89. Wilson MG: The natural history of rheumatic fever in the first three decades. *J Pediatr* 1937;10:456-465.
90. Wannamaker LW, Rammelkamp CH Jr, Denny FW, et al: Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin *Am J Med* 1951;10:673-681.
91. Houser HR, Eckhardt GC, Hahn EV, et al: Effect of Aureomycin treatment of streptococcal sore throat on the streptococcal carrier state, the immunologic response of the host and the incidence of acute rheumatic fever. *Pediatrics* 1953;12:593-601.
92. Cantanzars FJ, Brock L, Chamovitz R, et al: Effect of oxytetracycline therapy of streptococcal sore throat on the incidence of acute rheumatic fever. *Ann Intern Med* 1955; 42:345-352.
93. Stollerman GH, Russof JH, Hirschfield J: Prophylaxis against group A streptococci in rheumatic fever: Use of single monthly injections of benzathine penicillin. *N Engl J Med* 1955;252:787-792.
94. Wood HF, Feinstein AR, Taranta A, et al: Rheumatic fever in children and adolescents:III. Comparative effectiveness of three prophylactic regiments in preventing streptococcal infections and rheumatic recurrences. *Ann Intern Med* 1964;60(suppl 5):31-47.
95. Johnson RD, Hartman TL : Sulphadiazine resistant streptococcal infections in a civilian community *J Clin Invest* 26:325, 1947.
96. Lue

97. Feinstein AR, Stern EK, Spagnuolo M: The prognosis of acute rheumatic fever. Am Heart J 68:817-834, 1964
98. Spagnuolo M, Feinstein AR: Congestive heart failure and rheumatic activity in young patients with rheumatic heart disease. Pediatrics 33:653-660, 1964
99. Markowitz M, Gordis L. Rheumatic fever, 2nd Ed. Philadelphia, W.B. Saunders Company, 1972.

Table 1

The proportional incidence of group A streptococcal (GAS) pharyngitis in the Eastern Mediterranean Region; comparison with other countries.

Country	Year	Ref. (No.)	No. of patients	GAS* Pharyngitis (%)
Egypt	(1973)	(28)	156	19%*
Kuwait	(1984)	(29)	465	22%*
India	(1971)	(30)	248	14%*
USA	(1974)	(31)	5500	23%*

* Numbers are expressed as percentage of the total number with Pharyngitis.

Table 2

The antistreptococcal immune responses in children with rheumatic fever in countries with different climates.

Author	Ref. (No.)	Country	Climate	No. of Patients	GMT	
					ASO	AH
Bernhard & stollerman	(32)	USA	Temperate	31	497	578
Limson et al.	(33)	Philippines	Tropical	NA	419	NI
Majeed et al.	(34)	Kuwait	Subtropical	130	488	595

GMT : Geometric mean titer.

ASO : Antistreptolysin O.

AH : Anti hyaluro dinase.

NI : No information.

Table 3

The incidence of RF in countries of the Eastern Mediterranean Region. Comparison with other countries.

COUNTRY	YEAR	(REF) (NO.)	INCIDENCE (PER / 100,000)	AGE GROUP (YEARS)
KUWAIT	1985	(35)	31	5-14
IRAN	1972	(36)	58-100	ALL AGES
CYPRUS	1972	(36)	27-43	ALL AGES
SWEDEN	1985	(37)	0.2	0-15
USA	1978	(38)	9*	5-14
ENGLAND	1963	(36)	4.7	1-14

* 2.7 in all ages.

Table 4

Prevalence of the different serogroups of B-hemolytic streptococci(BHS) in normal asymptomatic school children in Kuwait: comparison with similar studies from temperate, subtropical, and tropical countries

Country	Reference No.	Climate	Years of study	No. of children	BHS Carrier rate (%)	Groups*	
						A (%)	C+G Others (%)
Czechoslovakia	(40)	Temperate	1967-1971	244	11.6-19.3	54	22 24
Netherlands	(41)	Temperate	1964-1965	412	51	61	28 11
Egypt	(42)	Subtropical	1967-1970	156	50	30	70
Kuwait	(39)	Subtropical	1978-1979	1041	47	22	74 4
Liberia	(43)	Tropical	1965-1966	72	49	20	65 15
Nigeria	(44)	Tropical	1971-1972	424	8	21	77 2
South India	(45)	Tropical	1957-1958	883	49	14	67 19

* Numbers expressed as percentage of the total.

Table 5

The clinical profile of acute rheumatic fever in studies reporting the initial attack only.

Clinical profile	Massel et al. 1958 (457 patients) (Boston, U.S.A.) (Ref. 68)	Feinstein and Spagnuolo 1962 (275 patients) (New York, U.S.A.) (Ref. 69)	Sanyal et al. 1974 (102 patients) (New Delhi, India) (Ref. 18)	Majeed et al. 1981 (210 patients) (Kuwait) (Ref. 19)
Arthritis	74%	76%	66.6%	79%
Carditis	52.5%	41.8%	33.7%	46.2%
Cardiomegaly without CHF	NI	10.9%	9.8%	10%
CHF	7.9%	5.8%	2%	4.8%
Pericarditis	6.3%	3.3%	1%	1.4%
Chorea	23%	7.6%	20.5%	7.6%
Erythema marginatum	10.5%	1%	1.9%	1.4%
Subcut. nod.	11.8%	4%	1.9%	0.5%
Mortality	1.6%	0.36%	0.98%	0.48%

NI, no information; CHF, congestive heart failure; Subcut. nod., subcutaneous nodules.

Table 6

THE EVOLUTION OF RHEUMATIC HEART DISEASE IN PATIENTS ON REGULAR SECONDARY PROPHYLAXIS IN THE DIFFERENT CLIMATES

Study	Ref.	Year Ref.	Climate	Patients		Recurrences		RHD*	
				N	No./years	N	RR**/patient/yr	N	PR***
U.K. - U.S. joint report.	(72)	(1960)	Temperate	324	1620	42	0.026	101	31%
Feinstein et al.	(73)	(1964)	Temperate	156	260	2	0.004	NA†	NA†
Tompkins et al.	(74)	(1972)	Temperate	115	565	1	0.001	30	26%
Sanyal et al.	(70)	(1982)	Tropical	65	325	2	0.006	23	35%
Majeed et al.	(71)	(1986)	Subtropical	66	383	2	0.005	15	23%†

* RHD : Rheumatic heart disease. **RR : Recurrence rate

***PR : Prevalence rate. † Not available.

† Not significantly different from the other studies ($p > 0.05$).